Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atorvastatin/ezetimibe - Merck & Co

Next Previous
X
Search
Drug Profile

Atorvastatin/ezetimibe - Merck & Co

Alternative Names: Ateroclar Combi; Atozet; Atozet Combination Tablets HD; Atozet Combination Tablets LD; Colmibe; Ezetimibe/atorvastatin; Kexrolt; Liptruzet; MK-0653c; Orvatez; SCH-900068; Sersemic; Tioblis; Zardiux; Zoletorv

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck/Schering-Plough Pharmaceuticals
  • Developer Merck & Co; Rovi
  • Class Amides; Antihyperlipidaemics; Azetidines; Fatty acids; Fluorobenzenes; Heptanoic acids; Propanols; Pyrroles
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypercholesterolaemia; Hyperlipidaemia

Most Recent Events

  • 15 Nov 2022 Launched for Hypercholesterolaemia in Chile (PO, Tablet)
  • 09 Nov 2022 Launched for Hypercholesterolaemia in France (PO, Tablet)
  • 09 Mar 2022 Atorvastatin/ezetimibe is still in phase III trials for Hypercholesterolaemia (Adjunctive treatment) in China (PO, Tablet) (NCT03768427)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top